MBRS-53. ENHANCED EFFICACY OF NANO-FORMULATED VISMODEGIB SHOWS THE POTENTIAL FOR POLYOXAZOLINE MICELLES TO IMPROVE DRUG DELIVERY TO BRAIN TUMORS

For the roughly 30% of medulloblastoma patients with SHH-subgroup tumors, drugs that disrupt SHH signaling offer the potential of improved efficacy with reduced toxicity compared to current, non-targeted treatment. The FDA-approved SMO inhibitor vismodegib, which targets SHH signaling at the cell me...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Hwang, Duhyeong, Zhao, Yuling, Liu, Hedi, Kabanov, Alexander, Gershon, Timothy, Sokolsky, Marina
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012939/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.498
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares